Építés alatt – nem éles oldal
Belépés
Leállítva1. fázis

Continued Treatment for Participants Enrolled in Studies of BXQ-350

A legfontosabb adatok

Ki végzi
Bexion Pharmaceuticals, Inc.
Hol
Cincinnati, Columbus és Lexington (Egyesült Államok)Mind a 3 helyszín megnézése
Azonosító
Állapot
Leállítva
Fázis
1. fázis
Résztvevők
5 fő vett részt
Kezdés
2020. jún. 8.
Befejezés
2024. szept. 23.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • BXQ-350
A regiszteradat frissítve
2024. december 20.
Miért állt le
Bexion Pharmaceuticals no longer has open studies in which subjects would be eligible to rollover and continue treatment under the BXQ-350.AE protocol. Therefore, no additional subjects will be enrolled in this trial.

Ki vehet részt

Életkor
1 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 2 feltétel megnézéseKevesebb

Ki vehet részt

  • Each subject must meet the following criteria:; Has participated in and completed all protocol-specified treatments through the required study observation period or time of closure for a prior Bexion-sponsored BXQ-350 clinical study; Has completed the End of Study visit of the prior Bexion-sponsored BXQ-350 clinical study; Did not meet any treatment discontinuation criteria of the original prior Bexion- sponsored BXQ-350 clinical study; Investigator opinion indicates that continued treatment with BXQ-350 is clinically appropriate for the subject; Provide signed, written informed consent prior to the initiation of any study-specific procedures (Consent from Guardians for minor children and patient assent according to Institution and Institutional Review Board (IRB) standards); Have a negative serum pregnancy test result within 28 days prior to the first continuing treatment assessment for females of child bearing potential (FCBP); not applicable to subjects who are unable to become pregnant, including those with tubal ligation, bilateral oophorectomy and/or hysterectomy); FCBP and male subjects whose sexual partner(s) are FCBP must agree to abstain from heterosexual activity or use a double barrier method of contraception (e.g., condom and occlusive cap with spermicide) or highly effective contraception (intrauterine device or system, established hormonal contraceptive methods on a stable dose from the time of the last menstrual cycle, or vasectomized partner with confirmed azoospermia) from the time of study entry to 1 month after the last day of treatment

Ki nem vehet részt

  • Subjects must not meet any of the following criteria:; Has any ongoing adverse event that could impact tolerability to BXQ-350; Receiving any other non-BXQ-350 study treatment modalities with curative intent, including investigational products other than BXQ-350; Are pregnant or nursing (lactating), where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive serum human chorionic gonadotropin (hCG) laboratory test

Helyszínek itt: Egyesült Államok

  • University of Cincinnati Barrett CenterCincinnati, Egyesült Államok
  • The Ohio State University Comprehensive Cancer CenterColumbus, Egyesült Államok
  • University of Kentucky/Markey Cancer CenterLexington, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

This is a study to allow continued treatment for participants enrolled in studies of BXQ-350. This study is intended only for those who have completed the required study observation period or are still on treatment upon the closure of their respective BXQ-350 clinical study. The additional treatment is optional and voluntary.

A vizsgálat csoportja

  • Continued TreatmentA vizsgált kezelés

    Subjects who have completed the required study observation period or are still on treatment upon the closure of their respective BXQ-350 clinical study, and who are judged by the Investigator to benefit from continued treatment with BXQ-350. Treatment will begin after completion of the End of Study visit of the prior BXQ-350 clinical study. The established safe dose of BXQ-350 from previous adult and pediatric phase 1 studies is 2.4 mg/kg and 3.2 mg/kg respectively once every 28 days (± 3 days). BXQ-350 will be administered intravenously at the same dose level and frequency the subject was receiving at the end of the prior BXQ-350 clinical study. Subjects receiving a reduced dose at the end of the prior BXQ-350 clinical study due to toxicity may continue to receive a reduced dose.

    Kezelés: BXQ-350

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
An Open-Label, Multi-Center, Rollover Study to Provide Continued Treatment Access for Participants Enrolled in Studies of BXQ-350
A regiszteradat frissítve
2024. december 20.